Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Researchers assessed data from 16 million patients from 2006 to 2020 taking semaglutide-based drugs; the active ingredient in Wegovy.

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

Ozempic can lead to weight loss; however, intuitive eating advocates believe listening to your body’s hunger signals garner ...

JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...

Cigna CEO David Cordani is not convinced of the benefits of GLP-1s for weight-loss patients and said the US is the only ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

The quick response that helped Nokia, Skype, Spotify and Klarna dominate their industries is now benefiting Nordic companies ...

U.S. Health and Human Services Secretary Robert F. Kennedy Jr.’s health team is getting into place, as the U.S. Senate ...